(CercleFinance.com) – Acticor Biotech announces regulatory approval of the LIBERATE clinical study, based on a long-standing collaboration with the University of Birmingham, and aimed at evaluating the tolerance and effectiveness of glenzocimab for height reduction of myocardial infarction.
This randomized, double-blind, placebo-controlled Phase 2b study will include more than 200 patients suffering from ST-segment elevation myocardial infarction (STEMI) undergoing percutaneous coronary intervention.
The study will be carried out at two hospitals in the UK, namely the Queen Elizabeth Hospital in Birmingham and the Northern General Hospital in Sheffield. Patient recruitment is expected to begin by the end of 2023.